ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

STX Shield Therapeutics Plc

1.65
-0.10 (-5.71%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -5.71% 1.65 1.60 1.70 1.90 1.625 1.75 15,893,319 11:54:33
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.47M -40.44M -0.0522 -0.32 12.79M
Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 1.75p. Over the last year, Shield Therapeutics shares have traded in a share price range of 1.075p to 12.75p.

Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £12.79 million. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.32.

Shield Therapeutics Share Discussion Threads

Showing 8526 to 8548 of 23250 messages
Chat Pages: Latest  342  341  340  339  338  337  336  335  334  333  332  331  Older
DateSubjectAuthorDiscuss
17/5/2021
17:13
How is the price doing in US market if still open?
78steve
17/5/2021
16:35
Closed at a 3 month high on decent volume.Bodes well for more gains tomorrow.
parob
17/5/2021
16:35
Hoping my double up today sneaked in under 55p. I left it with my broker and haven't heard what price he got yet.
donaferentes
17/5/2021
16:30
and a little jump at the end to get the share price rise to around 10%.

Which...as the man says in the Fast Show "Is nice"

purchaseatthetop
17/5/2021
16:01
shandypants....IMO this is what the American NEDs are there for. I bet they are running the US launch and that is why it will happen. They would never have come onboard without a serious amount of technical and logistical control and certainty.

That is why the RNS of the two NEDs was so critical in me adding and adding. It meant that STX were (finally) being professional.

That interview was in many ways dreadful. He got the incomes vague for years 1 to 3 and then did the same for years 4 to 5. No real clarity on the net income that would mean. Quite dreadful if you compare him to AN at AGL or JS at ITX who are clarity and conciseness.

However, he did commit to Q2 2021. Period.

purchaseatthetop
17/5/2021
15:56
Had another nibble today. So this should really be at 100p as it seems US launch going ahead shortly potential multimillion prospect. Dyor
78steve
17/5/2021
15:53
purchase - totally agree. End of Q2 launch always had a bit of contingency build in so he seems quite confident.
He starts the interview by re-iterating this date so if there were any doubts he would have been more vague on dates. I think the later comment re a couple of months was just him being a little nervous (he's not a great presenter/interviewee). He also said potential sales of $100m in the first 3 years - he meant by year 3, so again another slight slip. He also mentions how excited he is for the US launch, another good indicator IMHO.

shandypants2
17/5/2021
15:44
My view is that the US Launch is 100% on track and will be delivered. There is no way any sane CEO would state that it was happening and release the interview just a few weeks before the deadline. I hope.
purchaseatthetop
17/5/2021
15:41
My feeling is an "on track" US launch update plus a close above 60p and this will move very quickly to close the gap just above 100p on the chart.
parob
17/5/2021
15:36
I just added at 55.95p as my last previous buy on 11/5/21 at 55.6p had just been exceeded. Not a problem getting 4,000.
purchaseatthetop
17/5/2021
15:32
It is relentless and the weight of buying today could see this over 60p into the close imho...

gla

andyview
17/5/2021
15:28
Relentless buying and yes £1+ is a fair target - short term!
frrinvest
17/5/2021
15:19
For anyone who hasn't watched the Funky Finance video here's the link:hTTps://www.youtube.com/watch?v=8ZqdKDZpUBs&feature=youtu.be
parob
17/5/2021
15:17
Funky finance can up trumps yet again .
brownbear3
17/5/2021
14:27
Shield first US OTC trade in a few mins
growthinvestor2001
17/5/2021
14:16
Yes I picked up on that comment a couple of months which if taken literally could mean mid July which would be yet another delay .
we are already approaching 2 years since FDA approval just stating that Time is unbelievable it needs to be June from a confidence in management actually delivering on what’s been stated

best1467
17/5/2021
13:45
Thanks for link - I do hope TW isn't passing this off as his " mid May" update on US sales as it wasn't. Traders nearest he came to that was an apparently off the cuff remark of launching in "a couple of months". I expect sales before end Q2 as he has previously said ( I don't really as I have no confidence in the man in truth)
I hope the new investors aren't disappointed so quickly.

powerp2
17/5/2021
13:25
Steve, 200p valued STX at c£234m (117 m shares in issue).

Now with 216m shares it's equivalent to 108p.

So hopefully, once we start selling in the US and sentiment improves £1 is the short term target.

Tim on Proactive this morning

shandypants2
17/5/2021
13:10
thanks for that Parob...will listen later. hope it is 10% as good as AN on AGL at Zaks Traders.
purchaseatthetop
17/5/2021
12:25
New interview out this morning.All sounds on track for the US launch.TW:"We are going to be launching Accrufer in the US by the end of the 2nd quarter"hTTps://tinyurl.com/p6symev6Shield Therapeutics says OTCQX Best Market listing ahead of Accrufer US launch has 'great potential'Shield Therapeutics PLC's (LON:STX), Tim Watts talks to Proactive London about their new US stock market quote on the OTCQX Best Market.This decision is to support the upcoming launch of Accrufer in the US with the aim to increase relevance to US-based investors.Watts explains that they will face no additional reporting requirements as a result of the American listing, therefore the additional costs will be 'minimal'.Watts believes the drug has the potential to reach the realm of '£100mln worth of sales in the first three years and then on to 3-400mln by years five or six'.
parob
17/5/2021
11:48
It will be very interesting to see at 14.30 today when the new OTCQX market opens for STX shares in the USA for the first time whether we get a major boost. Might happen.
purchaseatthetop
17/5/2021
11:23
Lots of big buys going through today.
parob
17/5/2021
11:20
innittowinit.......you won it. My respect. Thanks
purchaseatthetop
Chat Pages: Latest  342  341  340  339  338  337  336  335  334  333  332  331  Older

Your Recent History

Delayed Upgrade Clock